Immuno-oncology company Targovax ASA (OSE:TRVX) revealed on Wednesday the receipt of the European patent that will protect its mutant-RAS specific neoantigen peptides, mutant RAS specific T cells and vaccines TG01 and TG02, for the treatment of cancer in combination with chemotherapies.

The European Patent, which has been assigned the no 3040320, has been awarded by the European Patent Office, with expiry until 6 May 2034, added the company.

According to the company, the proprietary mutant-RAS neoantigen vaccine platform is designed to treat patients with tumors harboring RAS mutations, which are a driving cause of cancer development and progression and is linked to poor prognosis. By inducing an anti-mutant-RAS specific immune response, TG01 and TG02 have the potential to delay disease progression and increase survival, with a favorable safety profile compared to chemotherapy and many other treatment options.

Under the company's recent Phase I/II clinical trial TG01-01 in resected pancreatic cancer with TG01 treatment in combination with the chemotherapeutic agent gemcitabine, the immune response was seen in 94% (30/32) of patients.